First Atom leverages our proprietary AI-enabled molecular design PRISM™ technology to identify novel protein pockets and rapidly design NCEs atom by atom, optimizing efficacy and safety. AI-driven target identification has caused biology to scale faster than translation capacity; First Atom addresses this critical bottleneck, rapidly translating targets into new medicines. PRISM™ enables value creation through partnership across the drug design process including (1) de novo target design (2) creation of new medicines and optimization of existing compounds  (3) identification of optimal patient cohorts and expansion of existing pipeline targets.

FirstAtom Therapeutics

Org chart

Teams

Offices

FirstAtom Therapeutics

Org chart

Teams

Offices

Related companies